



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/845,497	05/01/2001	Amina Odidi	9577-25 LAB	2340

7590

05/15/2002

Lola A. Bartoszewicz  
Sim & McBurney  
6th Floor  
330 University Avenue  
Toronto, ON M5G 1R7  
CANADA

EXAMINER

PRYOR, ALTON NATHANIEL

ART UNIT

PAPER NUMBER

1616

DATE MAILED: 05/15/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

active

↑  
encast = Polyethylene  
and  
...  
P.E.C.

# Office Action Summary

Application No.  
**09/845,497**

Applicant(s)  
**Odidi et al**

Examiner  
**Alton Pryor**

Art Unit  
**1616**



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_\_
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1, 6-9, 11, 15-17, and 21-33 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 1, 8, 9, 16, 26, and 31 is/are allowed.
- 6) ☒ Claim(s) 15, 17, 21, 23-25, 28-30, 32, and 33 is/are rejected.
- 7) ☒ Claim(s) 6, 7, 11, 22, and 27 is/are objected to.
- 8) ☐ Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some\* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_\_ 6) ☐ Other:

Art Unit: 1616

In the present instance, claim 15 recites the broad recitation sulfonylureas, and the claim also recites including glyburide, etc. which is the narrower statement of the range/limitation.

Regarding claims 24,25,28,29, the term "type" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

4. Claim 32 recites the limitation "0 % compression aid" and " 0% extrusion aid" in line 1 and 2. There is insufficient antecedent basis for this limitation in the claim.

***Claim Rejection under 35 U.S.C. 103(a)***

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 17,21,23,30,33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cheng et al (US 6,099,859; 8/8/00). Cheng teaches a extended time release formulation comprising an antihyperglycemic drug. The drug is formulated into a tablet which is encased in a semi-permeable membrane (polymer film). The polymer membrane is soluble at pH 7.5. Cheng teaches that the membrane is made of methacrylic acid copolymer comprising PEG, plasticizers, and excipients. Cheng also teaches that the time release period of antihyperglycemic drug is from 12-24 hours. See column 2 lines 16-43, column 3 line 30 - column 5, claim 17. Cheng does not

Art Unit: 1616

teach the formulation comprising the instant amounts of PEG. However, one having ordinary skill in the art would have been expected to determine the optimum amounts through routine experimentation. One would have been motivated to do this in order to make a formulation that would have the proper time release characteristic. In reference to the making of the instant invention, it is well known to compress active ingredients into tablets and to follow with the encasement of the tablet.

***Claim Objection / Allowable Subject Matter***

Claims 11,22,27 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The prior art does not suggest a time release tablet of the instant claims comprising shellac or zein. Claims 1,8,9,16,26,31 are allowable. The prior art does not teach or suggest the instant invention comprising the instant group of compression aids.


***Telephonic Inquiry***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton Pryor whose telephone number is (703) 308-4691. The examiner can normally be reached on Monday through Friday from 8:00 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees, can be reached on (703) 308-4628. The fax phone number for this Group is (703) 308-4556.

Art Unit: 1616

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

  
Alton Pryor  
PRIMARY EXAMINER  
ALTON N. PRYOR  
PRIMARY EXAMINER  
Primary Examiner, AU 1616

3/28/03